Rajnish Wellness

BSE: RAJNISH · Pharmaceuticals

—
52W Range₹0 – ₹1

Limited coverage

We are not actively covering this company or have limited coverage today. Click to request coverage.

Snapshot

Unlock Rajnish Wellness's vital signs

Growth · Profitability · Valuation · Strength · Conviction

Company Overview

Business

Rajnish Wellness is an Indian company specialising in the manufacturing and marketing of ayurvedic, herbal, and consumer healthcare products. The firm operates a diversified portfolio ranging from sexual wellness items to medicinal supplements and manages the Dava India retail pharmacy franchise network.

Business Model

The company generates revenue through the sale of consumer wellness products under brands like PlayWin and by operating a franchise-based retail pharmacy model. It leverages digital marketing and an expanding physical distribution network to reach both urban and rural markets.

Management Commentary

Management is focused on transitioning the company into an integrated wellness entity by scaling its retail footprint and diversifying into high-margin lifestyle and energy-boosting products.

Growth Outlook

Growth is driven by the expansion of the Dava India franchise network and the continuous introduction of new lifestyle wellness solutions. The company aims to capture a larger market share by strengthening its distribution reach across India.

Key Risks

  • Regulatory Compliance. The company faces stringent regulatory oversight regarding the manufacturing and marketing of ayurvedic and medicinal products.
  • Market Competition. Intense competition in the consumer healthcare and generic medicine space could pressure margins and market share.
  • Franchise Operational Risk. The reliance on the Dava India franchise network introduces risks related to brand consistency and operational control across diverse locations.

Start your research today

Unlock AI insights, financials, peers and live data on Rajnish Wellness and 5,000+ companies — free.

Start your research

Key Metrics

REVENUE

₹142 Cr

TTM · standalone

+192.0%YoY

NET PROFIT

₹6 Cr

TTM · standalone

+501.0%YoY

EPS

₹0.06

TTM · standalone

+500.0%YoY

RETURN ON EQUITY

6.6%

TTM · standalone

+5.4 ppYoY

RETURN ON CAPITAL EMPLOYED

9.0%

TTM · standalone

+7.4 ppYoY

P/E

6.0x

Q4 FY26 · standalone

6.0 vs 13.7x5Y avg

EV/EBITDA

4.8x

Q4 FY26 · standalone

4.8 vs 33.2x5Y avg

EBITDA MARGIN

5.8%

TTM · standalone

+2.8 ppYoY

NET PROFIT MARGIN

4.6%

Q4 FY26 · standalone

-3.4 ppYoY

DEBT TO EQUITY

0.0x

Q4 FY26 · standalone

+0.00xYoY

Peers · Pharmaceuticals

CompanyMkt CapP/EEV/EBITDARev Gr YoYEBITDA MgnROEROCE1Y Return
Rajnish WellnessRAJNISH
₹40 Cr6.004.81192.0%5.8%6.6%9.0%-61.3%
TranschemTRANSCHEM
₹502 Cr75.6252.99-100.0%177.7%8.3%10.6%+600.8%
Albert DavidALBERTDAVD
₹501 Cr21.6713.1911.4%11.0%5.8%7.5%+10.3%
Haleos Labs LimitedHALEOSLABS
₹457 Cr28.5112.83-3.1%13.6%7.4%10.3%—
Medicamen BiotecMEDICAMEQ
₹434 Cr43.0019.7624.7%11.3%4.1%6.2%+5.9%
Jenburkt Pharmaceuticals LimitedJENBURPH
₹420 Cr12.308.20—30.0%16.7%21.5%-15.2%

As of Q4 FY26

Financials